Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $29,850.96 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Paul Kearney sold 4,078 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $29,850.96. Following the completion of the transaction, the insider now owns 176,889 shares of the company’s stock, valued at approximately $1,294,827.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sera Prognostics Stock Down 2.7 %

Shares of SERA traded down $0.20 during mid-day trading on Tuesday, hitting $7.24. 79,534 shares of the company’s stock traded hands, compared to its average volume of 175,932. Sera Prognostics, Inc. has a 1 year low of $1.65 and a 1 year high of $12.35. The firm has a market capitalization of $241.59 million, a P/E ratio of -7.31 and a beta of 1.04. The business’s 50-day moving average price is $7.41 and its 200-day moving average price is $7.68.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. purchased a new position in shares of Sera Prognostics in the 1st quarter valued at $18,420,000. AWM Investment Company Inc. lifted its position in Sera Prognostics by 56.0% during the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after acquiring an additional 209,762 shares during the period. Bank of New York Mellon Corp lifted its position in Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after acquiring an additional 75,441 shares during the period. Ballentine Partners LLC acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at about $294,000. Finally, Twelve Points Wealth Management LLC acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at about $257,000. 54.64% of the stock is owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.